You Started With One. Now You Need Three. Here Is What Your Brain Is Actually Telling You.
By Dr. Ben Lynch, ND | Bestselling Author of Dirty Genes | Founder, Seeking Health
KEY TAKEAWAYS
- You are not using more Zyn because you have weak willpower. Your brain is adapting to the signal. That is basic receptor biology.
- Nicotine pouches create a fast, high peak in blood nicotine. That speed is why they feel so effective at first. It is also why they stop working.
- You are not nicotine-deficient. Your body does not make nicotine. Food does not supply it. The relief you feel points to something else.
- Nicotine activates only half your acetylcholine receptor system. The other half, responsible for long-term memory, gut function, and nervous system regulation, goes untouched.
- There is a specific neurotransmitter your brain is running low on. Nicotine is borrowing its receptors. It is not replacing what is missing.
It Started Working. Now It Barely Does.
You remember the first time.
One pouch and the fog cleared. You sat down and actually focused. You felt sharp in a way you had not in a while. Maybe calmer. Maybe more yourself.
So you used it again.
Now look where you are. You are going through more pouches per day than you intended. You have switched to a stronger mint. The same effect that used to arrive in ten minutes takes longer to show up, and it does not last as long. You notice you are spending real money on this every week. And somewhere in the back of your mind, you are aware that it is not working the way it used to.
That is not a personal failure. That is your brain adapting to a signal.
Something real is happening here. I want to help you understand what it is, because once you do, the path forward becomes obvious.
This is Part 1 of a three-part series. By the end of Part 3, you will know exactly what your brain is running low on, why nicotine is only a partial and temporary substitute, and what to actually do about it. The craving does not have to be permanent. But it will not go away until you address what is actually depleted.
Let us start with what nicotine is doing in your brain right now.
Why It Worked in the First Place
Nicotine fits a specific family of receptors in your brain called nicotinic receptors. These receptors are part of a much larger signaling system that governs attention, alertness, working memory, motivation, and your body's ability to quiet inflammation.
When nicotine binds to the alpha-4-beta-2 receptors in your prefrontal cortex, it sharpens working memory and attention.¹
When it hits alpha-7 receptors on immune cells in your brain, it partially activates a specific anti-inflammatory pathway that can reduce cytokine activity.
When it activates dopamine neurons in a part of the brain called the ventral tegmental area, it triggers a release of dopamine into the nucleus accumbens. That is the reward signal. That feeling of motivation and clarity is dopamine.
All of that is real. All of it is pharmacologically documented. You were not imagining the benefit.
The problem is not that nicotine does not work. The problem is how it works and what happens next.
Why It Stopped Working as Well
Your brain's receptors are not passive. They respond to what they experience.
Acetylcholine, the neurotransmitter these receptors are designed for, is released in precise, brief pulses at the synapse. It binds, signals, and clears in milliseconds. The receptor resets. The system stays calibrated.
Nicotine from a pouch behaves differently. It creates a sustained rise in blood nicotine that lasts for an extended period. The receptor stays occupied far longer than it normally would. When a receptor is continuously stimulated like that, it protects itself.
First, it desensitizes. It temporarily stops responding.² This is not damage. It is a regulated shutdown to prevent overstimulation.
Second, with repeated exposure, the receptor downregulates. The brain reduces how many of those receptors are available at the surface. Fewer receptors means the same dose of nicotine produces less effect.
This is tolerance. It is not a sign that you need more willpower. It is receptor pharmacology.
Pouches drive this process faster than patches. A pouch creates a sharp, high peak in blood nicotine.³ That spike is exactly what accelerates alpha-7 receptor desensitization. Patches deliver nicotine slowly over hours, which is why researchers use patches in clinical settings rather than pouches, gum, or vapes. The delivery speed matters.
You feel the consequence of this every time you notice the pouch is not hitting the same way it used to. Your brain adapted. It built tolerance. So you used more. Or stronger. And the cycle repeated.
The costs add up. The results do not.
You Are Not Running Low on Nicotine
Before we get to what is actually depleted, I want to establish something important.
You are not nicotine-deficient.
Your body does not make nicotine. There is no nicotine pathway. No nicotine enzyme. No biological system that requires nicotine to function. While nightshade vegetables like tomatoes and peppers contain trace amounts, the quantities are so small they have no pharmacological effect. No one develops cognitive decline from a tomato shortage.
´ Nicotine is not a nutrient. There is no deficiency state.
So when nicotine makes you feel better, something else is going on. It is not fixing a nicotine shortage. It is activating receptors that are not getting enough of what they are supposed to receive.
Think about that for a moment.
You feel sharper, calmer, more focused when nicotine hits those receptors. Which means those receptors were underactivated before the nicotine arrived. Which means the molecule that is supposed to be activating them is running low.
What molecule is that?
That is what Part 2 covers in detail. But I want to give you enough here to understand why nicotine is a poor long-term substitute.
The Neurotransmitter Your Brain Is Actually Missing
Those receptors nicotine is activating belong to the acetylcholine system. Acetylcholine is your brain's most underappreciated neurotransmitter, and it is one of the most important.†
It governs sustained attention and task focus. It drives memory consolidation, the process of moving information from short-term to long-term storage. It regulates gut motility and digestion. It controls heart rate variability. It mediates a specific anti-inflammatory pathway that acts as your brain's brake on runaway inflammation.†
When acetylcholine is adequate, you can hold a thought. You can learn and retain. Sleep is deep and restorative. Digestion works. Mood is stable.†
When it runs low, the opposite happens. Focus fractures. Word retrieval slows. Sleep gets shallower. Digestion slows. You feel blunted, flat, not quite yourself.
That symptom cluster is exactly what nicotine temporarily relieves. Because nicotine is sitting in the acetylcholine receptors and doing a partial impression of the neurotransmitter that belongs there.
Partial is the key word.
Why Nicotine Only Solves Half the Problem
The acetylcholine receptor system has two main branches. Nicotinic receptors, which nicotine activates. And muscarinic receptors, which nicotine does not touch at all.
Nicotine has zero affinity for muscarinic receptors.⁵ None.
The muscarinic branch is where long-term memory gets consolidated. The M1 receptor in the hippocampus and cortex files information from short-term into permanent storage. That requires actual acetylcholine. Nicotine does not reach it.
The M2 receptor regulates heart rate and heart rate variability, the measure of autonomic nervous system flexibility that researchers now track as a reliable marker of overall health. Also untouched.
The M3 receptor drives gut motility, glandular secretion, and digestion. If your gut has been slow or sluggish, this is part of the picture. Nicotine does not address it.
This is why people who rely on nicotine pouches often notice incomplete improvement. They feel more alert but cannot retain what they are learning. They feel sharper in the moment but the fog comes back harder when the pouch wears off. The nicotinic half of the system gets some signal. The muscarinic half gets nothing.
You are using an increasingly expensive partial solution for a problem that has a real fix.
Why So Many People Noticed This After Illness
For a significant portion of people now relying on nicotine products, something specific happened.
Research published in 2023 showed that the SARS-CoV-2 spike protein interacts directly with nicotinic acetylcholine receptors.⁶ The spike protein competes with proteins that maintain alpha-7 receptors at the cell surface. The result is fewer functional receptors and reduced acetylcholine signaling.
At the same time, illness-driven neuroinflammation upregulates an enzyme called acetylcholinesterase, which breaks down acetylcholine faster than normal.⁷ More of that enzyme means acetylcholine gets destroyed before it can act.
The result is a self-reinforcing loop. Less acetylcholine means the anti-inflammatory brake fails. More inflammation means more acetylcholinesterase. More acetylcholinesterase means less acetylcholine. The loop does not self-correct.
For these people, nicotine works fast because it bypasses the acetylcholine production problem entirely. It activates the receptors directly. That is real relief. It is also temporary relief that does nothing about what started the problem.
There Is a Real Fix
This is where I want to leave you with something different from the usual conversation about nicotine use.
You are not broken. You are not addicted in the conventional sense, where the substance is the problem. You are running low on a neurotransmitter your brain can produce and restore. Nicotine is a substitute for it. A poor one. A partial one. One that is getting more expensive and less effective.
The craving you feel is not random. It is a signal. Your brain is reaching for a receptor activator because the one it makes itself is not keeping up with demand.
Your brain can make more of what it needs. That is the difference between nicotine and what it is standing in for. One comes in a pouch. The other comes from your own biochemistry.
Part 2 of this series explains exactly why acetylcholine runs low: what your brain requires to produce it, where the process breaks down, and which genetic variants make some people significantly more vulnerable than others. It is not complicated. And it is not a life sentence.
Part 3 covers the protocol: the specific nutrients, the sequencing, the signs that you are actually recovering. When acetylcholine production restores, the nicotine craving reduces on its own without effort. That is not a theory. That is the clearest sign the underlying deficit is actually closing.
You do not have to keep spending more for less. The path out runs through what is actually depleted.
Coming Up in This Series
Part 2: Why Your Brain Is Low on Acetylcholine. The nutrients required to produce it, where production breaks down, and the genetic factors that make some people far more vulnerable.
Part 3: The Restoration Protocol. The specific steps to rebuild acetylcholine production, and why the nicotine craving fades organically when you do.
References
- Newhouse PA, Kellar K, Aisen P et al. Nicotine treatment of mild cognitive impairment: 6-month double-blind pilot RCT (n=74). Neurology. 2012;78:91-101. PMID 22232050.
- Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol. 2007;47:699-729. PMID 17009926.
- Perriot J, Underner M et al. Transdermal nicotine in non-smokers: systematic review for dose escalation guidance. Eur J Clin Pharmacol. 2021. PMC8183099.
- Siegmund B, Leitner E, Pfannhauser W. Determination of nicotine content of various edible nightshades and their products. J Agric Food Chem. 1999;47(8):3113-3120. PMID 10552617.
- Colovic MB, Krstic DZ, Lazarevic-Pasti TD et al. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315-335. PMID 24179466.
- Parris MS, Bhatt DL, Bhatt M et al. SARS-CoV-2 spike protein S12 region downregulates surface alpha-7 nAChR expression via competition with chaperones RIC3 and Bcl-2. PMC9923440. [in vitro; human data pending]
- Scherer EB, Loureiro SO, Marisco PC et al. Mild hyperhomocysteinemia increases brain acetylcholinesterase and proinflammatory cytokines in rats. Mol Neurobiol. 2014;50(2):589-596. PMID 24590316. [animal model]
† This content is for educational purposes only and has not been evaluated by the Food and Drug Administration. It is not intended to diagnose, treat, cure, or prevent any disease.
